A detailed history of Abrdn PLC transactions in I Mab stock. As of the latest transaction made, Abrdn PLC holds 162,580 shares of IMAB stock, worth $146,322. This represents 0.0% of its overall portfolio holdings.

Number of Shares
162,580
Previous 162,580 -0.0%
Holding current value
$146,322
Previous $271,000 25.83%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Jan 31, 2024

BUY
$1.21 - $1.9 $196,721 - $308,902
162,580 New
162,580 $308,000
Q1 2022

May 04, 2022

SELL
$12.54 - $46.93 $54,937 - $205,600
-4,381 Closed
0 $0
Q4 2021

Feb 08, 2022

SELL
$45.28 - $74.5 $4,754 - $7,822
-105 Reduced 2.34%
4,381 $208,000
Q3 2021

Nov 15, 2021

SELL
$57.18 - $84.43 $11,550 - $17,054
-202 Reduced 4.31%
4,486 $325,000
Q2 2021

Aug 10, 2021

BUY
$47.86 - $83.95 $224,367 - $393,557
4,688 New
4,688 $394,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $74.8M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Abrdn PLC Portfolio

Follow Abrdn PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Abrdn PLC, based on Form 13F filings with the SEC.

News

Stay updated on Abrdn PLC with notifications on news.